Literature DB >> 9762929

Immunohistochemical evaluation of thymidylate synthase in gastric carcinoma using a new polyclonal antibody: the clinical role of thymidylate synthase as a prognostic indicator and its therapeutic usefulness.

T Kuniyasu1, T Nakamura, Y Tabuchi, Y Kuroda.   

Abstract

BACKGROUND: Before this study was conducted, the clinical and therapeutic significance of immunohistochemical evaluation of thymidylate synthase (TS) in patients with gastric carcinoma had not yet been clarified.
METHODS: TS was immunohistochemically evaluated in 134 gastric carcinomas using anti-TS antibody. TS expression, 11 clinicopathologic variables, and survival were studied, and the correlations among them were investigated.
RESULTS: The groups with high and low TS levels consisted of 56 and 78 patients, respectively. Granular cytoplasmic staining patterns of tumor cells were produced by immunohistochemical staining of the gastric carcinoma tissues. The grade of TS staining was significantly correlated with three clinicopathologic variables: depth of invasion, peritoneal metastasis, and stage of the carcinoma (P < 0.05). A univariate analysis revealed that the 5-year survival was significantly better for the low TS group than for the high TS group (P < 0.05): 65.2% for the low TS group and 43.2% for the high TS group. The group with high grade TS staining who received chemotherapy because of the advanced stage of their disease had worse prognoses even if they received adjuvant chemotherapy. A multivariate analysis revealed that four variables (peritoneal metastasis, lymphatic invasion, liver metastasis, and TS staining grade) independently contributed to survival (P < 0.05). The hazard ratio for the group with low grade TS staining was 0.464 compared with the group with high grade staining.
CONCLUSIONS: The immunohistochemical evaluation of TS using this anti-TS antibody may be clinically and therapeutically useful in determining the prognosis of gastric carcinoma patients.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9762929     DOI: 10.1002/(sici)1097-0142(19981001)83:7<1300::aid-cncr5>3.0.co;2-m

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  14 in total

1.  A long-time survivor of alpha-fetoprotein-producing gastric cancer successfully treated by fluoropyrimidine-based chemotherapy: a case study.

Authors:  Masatsugu Hiraki; Seiji Sato; Keita Kai; Takao Ohtsuka; Naohiko Kohya; Yoshihiko Kitajima; Yuji Nakafusa; Osamu Tokunaga; Kohji Miyazaki
Journal:  Clin J Gastroenterol       Date:  2009-09-09

2.  Prognostic value of thymidine phosphorylase activity in liver tissue adjacent to hepatocellular carcinoma.

Authors:  Takahiro Ezaki; Toru Ikegami; Takashi Maeda; Tomomi Yamada; Teruyoshi Ishida; Makoto Hashizume; Yoshihiko Maehara
Journal:  Int J Clin Oncol       Date:  2005-06       Impact factor: 3.402

3.  Prognostic Value of c-MET Expression in Patients With Pancreatic Cancer Receiving Adjuvant and Neoadjuvant Chemoradiation Therapy.

Authors:  Kyle C Cuneo; Meredith A Morgan; Kent A Griffith; Peter G Hawkins; Joel K Greenson; Edgar Ben-Josef; Theodore S Lawrence; Mark M Zalupski
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-10-28       Impact factor: 7.038

4.  Mechanism of 5-fluorouracil required resistance in human hepatocellular carcinoma cell line Bel(7402).

Authors:  Jing Jin; Min Huang; Huai-Ling Wei; Geng-Tao Liu
Journal:  World J Gastroenterol       Date:  2002-12       Impact factor: 5.742

Review 5.  Prediction of clinical outcome of fluoropyrimidine-based chemotherapy for gastric cancer patients, in terms of the 5-fluorouracil metabolic pathway.

Authors:  Wataru Ichikawa
Journal:  Gastric Cancer       Date:  2006       Impact factor: 7.370

6.  Expression of thymidylate synthase determines the response of gastric cancer patients undergoing gastrectomy to 5-fluorouracil-based adjuvant chemotherapy.

Authors:  Chun-Nan Yeh; Shih-Ming Jung; Tsung-Wen Chen; Tsann-Long Hwang; Yi-Yin Jan; Miin-Fu Chen
Journal:  Langenbecks Arch Surg       Date:  2009-12-10       Impact factor: 3.445

7.  Association of gastric and intestinal phenotypic marker expression of gastric carcinomas with tumor thymidylate synthase expression and response to postoperative chemotherapy with 5-fluorouracil.

Authors:  Yusuke Tajima; Tadakazu Shimoda; Yukihiro Nakanishi; Noboru Yokoyama; Takayuki Tanaka; Kouji Shimizu; Toyohiko Saito; Masatoshi Kawamura; Mitsuo Kusano; Kazuhide Kumagai
Journal:  J Cancer Res Clin Oncol       Date:  2003-10-24       Impact factor: 4.553

8.  Over-expression of FRZB in gastric cancer cell suppresses proliferation and induces differentiation.

Authors:  Ying Qu; Jian-Fang Li; Qu Cai; Yun-Wei Wang; Qin-Long Gu; Zheng-Gang Zhu; Bing-Ya Liu
Journal:  J Cancer Res Clin Oncol       Date:  2007-08-07       Impact factor: 4.553

9.  Immunohistochemical expression of thymidylate synthase and prognosis in gastric cancer patients submitted to fluoropyrimidine-based chemotherapy.

Authors:  Marina Alessandra Pereira; Marcus Fernando Kodama Pertille Ramos; Andre Roncon Dias; Sheila Friedrich Faraj; Cinthya Dos Santos Cirqueira; Evandro Sobroza de Mello; Bruno Zilberstein; Venancio Avancini Ferreira Alves; Ulysses Ribeiro
Journal:  Chin J Cancer Res       Date:  2018-10       Impact factor: 5.087

10.  Expression of multidrug resistance-associated protein1,P-glycoprotein, and thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection.

Authors:  J-H Choi; H-Y Lim; H J Joo; H S Kim; J W Yi; H C Kim; Y K Cho; M W Kim; K B Lee
Journal:  Br J Cancer       Date:  2002-05-20       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.